Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Definium Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Definium Therapeutics, Inc.’s stock price such as:

• Definium Therapeutics, Inc.’s current stock price and volume
• Why Definium Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for DFTX from analysts
• DFTX’s stock price momentum as measured by its relative strength

About Definium Therapeutics, Inc. (DFTX)

Before we jump into Definium Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Want to learn more about Definium Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Definium Therapeutics, Inc..

Definium Therapeutics, Inc.’s Stock Price as of Market Close

As of June 25, 2026, 9:31 AM, CST, Definium Therapeutics, Inc.’s stock price was $41.900.

Definium Therapeutics, Inc. is down 0.55% from its previous closing price of $42.130.

During the last market session, Definium Therapeutics, Inc.’s stock traded between $41.590 and $42.500. Currently, there are approximately 108.79 million shares outstanding for Definium Therapeutics, Inc..

Definium Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Definium Therapeutics, Inc. Stock Price History

Definium Therapeutics, Inc.’s (DFTX) price is currently up 73.21% so far this month.

During the month of June, Definium Therapeutics, Inc.’s stock price has reached a high of $44.530 and a low of $21.690.

Over the last year, Definium Therapeutics, Inc. has hit prices as high as $44.535 and as low as $6.400.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Definium Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 24, 2026, there was 1 analyst who downgraded Definium Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Definium Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Definium Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Definium Therapeutics, Inc. (DFTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Definium Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 24, 2026, Definium Therapeutics, Inc. has a weighted four-quarter relative price strength of 62.04%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Definium Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Definium Therapeutics, Inc. Stock Price: Bottom Line

As of June 25, 2026, Definium Therapeutics, Inc.’s stock price is $41.900, which is down 0.55% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Definium Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.